CTA 313
Alternative Names: CTA-313Latest Information Update: 11 Mar 2026
At a glance
- Originator Nanjing Bioheng Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
- Preclinical Neurological disorders